Process for visualizing tissue metabolism using oxygen-17
    1.
    发明授权
    Process for visualizing tissue metabolism using oxygen-17 失效
    使用氧17观察组织代谢的过程

    公开(公告)号:US5339814A

    公开(公告)日:1994-08-23

    申请号:US869547

    申请日:1992-04-14

    申请人: Sigmund E. Lasker

    发明人: Sigmund E. Lasker

    摘要: The present invention provides a process for visualizing tissue metabolism in a subject comprising injecting .sup.17 O.sub.2 into the peritoneal cavity of a subject and detecting formed H.sub.2.sup.17 O in tissues of the subject. The .sup.17 O.sub.2 is injected as a gas or as microbubbles formed from an aqueous protein solution.

    摘要翻译: 本发明提供了一种可视化受试者中的组织代谢的方法,包括将17O2注射到受试者的腹膜腔中并检测受试者组织中形成的H217O。 作为气体或作为由蛋白质水溶液形成的微泡注入17O2。

    Organometallic diphenyl hydrantoins and uses thereof
    2.
    发明授权
    Organometallic diphenyl hydrantoins and uses thereof 失效
    有机金属二苯基乙内酰脲及其用途

    公开(公告)号:US5439903A

    公开(公告)日:1995-08-08

    申请号:US178768

    申请日:1994-01-07

    申请人: Sigmund E. Lasker

    发明人: Sigmund E. Lasker

    CPC分类号: C07D233/74 A61F2013/15032

    摘要: Stable, organometallic complexes of 5,5-diphenyl-2,4 imidazolidenedione (diphenyl hydantoin) are versatile biocides, effective when applied topically or parenterally to animal tissue, and when applied topically to plants. The diphenyl Hydantoin complexes are seen to prevent animal and plant tissue infections, and may be combined with other materials to inhibit infection.

    摘要翻译: 5,5-二苯基-2,4-咪唑烷二酮(二苯基乙内酰脲)的稳定的有机金属络合物是通用杀生物剂,当局部或肠胃外给动物组织施用时,当局部施用于植物时有效。 可以看出二苯基乙内酰脲复合物可以防止动物和植物组织感染,并可与其他物质结合以抑制感染。

    Method for introducing oxygen-17 into tissue for imaging in a magnetic
resonance imaging system
    3.
    发明授权
    Method for introducing oxygen-17 into tissue for imaging in a magnetic resonance imaging system 失效
    在磁共振成像系统中将氧-17引入用于成像的组织中的方法

    公开(公告)号:US4996041A

    公开(公告)日:1991-02-26

    申请号:US234339

    申请日:1988-08-19

    摘要: A diagnostic imaging agent is provided for use in conjunction with a magnetic resonance imaging system for the imaging of spacial oxygen distribution in tissue. The imaging agent is comprised of a complex of oxygen-17, a biologically acceptable liquid carrier, such as a perfluorinated compound, and an emulsifying agent, and wherein the agent has an average particle size of less than about 0.6 microns, and an ionic composition essentially equal to that of blood. Useful information can be obtained, and in certain instances, therapy administered, by a non-envasive imaging technique relative to tissue perfusion by .sup.19 F-NMR (imaging of .sup.19 F) and oxygen utilization by .sup.1 H-NMR (imaging of H.sub.2.sup.17 O as a metabolite).

    摘要翻译: 提供诊断成像剂与磁共振成像系统一起用于组织中空间氧分布的成像。 成像剂由氧-17的复合物,生物学上可接受的液体载体如全氟化合物和乳化剂组成,并且其中所述试剂的平均粒径小于约0.6微米,并且离子组成 基本上等于血液。 可以获得有用的信息,在某些情况下,通过非侵入性成像技术相对于通过19F-NMR(19F成像)的组织灌注和通过1 H-NMR(H217O作为代谢物的成像)的氧利用来施用治疗。

    Modified Glycosaminoglycans, Pharmaceutical Compositions and Methods for Oral Delivery Thereof
    4.
    发明申请
    Modified Glycosaminoglycans, Pharmaceutical Compositions and Methods for Oral Delivery Thereof 审中-公开
    改性糖胺聚糖,药物组合物和口服方法

    公开(公告)号:US20090275543A1

    公开(公告)日:2009-11-05

    申请号:US12365470

    申请日:2009-02-04

    IPC分类号: A61K31/56 C07J31/00

    CPC分类号: A61K31/727

    摘要: This invention provides a composition comprising a depolymerized glycosaminoglycan or derivative thereof covalently linked to a bile acid. This invention also provides a pharmaceutical composition comprising a depolymerized glycosaminoglycan or derivative thereof covalently linked to a bile acid and a pharmaceutically acceptable carrier. Finally, this invention provides a method for orally delivering heparin to a subject comprising administering to the subject a pharmaceutically effective amount of a pharmaceutical composition comprising a glycosaminoglycan or derivative thereof covalently linked to a bile acid and (b) a pharmaceutically acceptable carrier.

    摘要翻译: 本发明提供了包含与胆汁酸共价连接的解聚的糖胺聚糖或其衍生物的组合物。 本发明还提供了包含与胆汁酸共价连接的解聚的糖胺聚糖或其衍生物和药学上可接受的载体的药物组合物。 最后,本发明提供了一种向受试者口服输送肝素的方法,包括向受试者施用药学有效量的包含与胆汁酸共价连接的糖胺聚糖或其衍生物的药物组合物和(b)药学上可接受的载体。

    Composition containing silver ammonium phenytoin complex and a phenytoin
and use of said composition
    5.
    发明授权
    Composition containing silver ammonium phenytoin complex and a phenytoin and use of said composition 失效
    含有铵铵苯妥英复合物和苯妥英的组合物和所述组合物的用途

    公开(公告)号:US5571521A

    公开(公告)日:1996-11-05

    申请号:US387251

    申请日:1995-02-13

    申请人: Sigmund E. Lasker

    发明人: Sigmund E. Lasker

    摘要: Compositions containing silver ammonium phenytoin complex and a phenytoin are usefully employed, particularly when applied topically, for the treatment of animal or human tissue, for wound healing and are useful in wound dressing preparations for the prevention or treatment of infections. The compositions are usefully applied by direct topical application to the wound or tissue to be treated or may be directly applied to the wound or tissue or incorporated in or coated on a dressing, such as a bandage.

    摘要翻译: 包含银铵苯妥英复合物和苯妥英的组合物特别适用于局部应用于动物或人体组织的治疗用于伤口愈合,并且可用于预防或治疗感染的伤口敷料制剂中。 通过直接局部施用将组合物有效地施用于待治疗的伤口或组织,或者可以直接施用到伤口或组织上或掺入或涂覆在诸如绷带的敷料上。

    Organometallic diphenyl hydantoin
    6.
    发明授权
    Organometallic diphenyl hydantoin 失效
    有机金属二苯基乙内酰脲

    公开(公告)号:US5298624A

    公开(公告)日:1994-03-29

    申请号:US974686

    申请日:1992-11-12

    申请人: Sigmund E. Lasker

    发明人: Sigmund E. Lasker

    CPC分类号: C07D233/74 A61F2013/15032

    摘要: Stable, organometallic complexes of 5,5-diphenyl-2,4 imidazolidenedione (diphenyl hydantoin) are versatile biocides, effective when applied topically or parenterally to animal tissue, and when applied topically to plants. The diphenyl Hydantoin complexes are seen to prevent animal and plant tissue infections, and may be combined with other materials to inhibit infection.

    摘要翻译: 5,5-二苯基-2,4-咪唑烷二酮(二苯基乙内酰脲)的稳定的有机金属络合物是通用杀生物剂,当局部或肠胃外给动物组织施用时,当局部施用于植物时有效。 可以看出二苯基乙内酰脲复合物可以防止动物和植物组织感染,并可与其他物质结合以抑制感染。

    Antithrombotic agent
    7.
    发明授权
    Antithrombotic agent 失效
    抗血栓剂

    公开(公告)号:US4533549A

    公开(公告)日:1985-08-06

    申请号:US580761

    申请日:1984-02-17

    申请人: Sigmund E. Lasker

    发明人: Sigmund E. Lasker

    IPC分类号: C08B37/10 A61K31/725

    摘要: The object of the invention is to provide a new antithrombotic agent.Coagulation of blood acts through a cascade of stages, the mechanisms and interaction of which have not been fully clarified. The present invention provides a derivative of heparin which can be administered orally, topically, or parenterally to antagonize the effect of factor Xa to a greater extent than commercial porcine heparin. In addition, the derivative has insignificant USP anticoagulant and platelet aggregating activities.The heparin derivative according to the invention, has a molecular weight of from about 2,500 to about 4,000 daltons, gives a positive metachromatic test for sulfated polysaccharides. Preferably, when isolated as the sodium salt, the derivative contains by elemental analysis about 26.2% carbon, 4.33% hydrogen, 1.98% nitrogen, 7.1% sulfur, and 9.8% sodium, the molar ratio C:N:S:Na being about 10:1.5:2:4.

    摘要翻译: 本发明的目的是提供一种新的抗血栓形成剂。 通过一系列阶段的凝血作用,其机制和相互作用尚未得到充分阐明。 本发明提供可以口服,局部或胃肠外给药以比商业猪肝素更大程度地拮抗因子Xa的作用的肝素衍生物。 此外,该衍生物具有微不足道的USP抗凝血剂和血小板聚集活性。 根据本发明的肝素衍生物具有约2,500至约4,000道尔顿的分子量,给出硫酸化多糖的阳性异染色试验。 优选地,当作为钠盐分离时,衍生物通过元素分析包含约26.2%的碳,4.33%的氢,1.98%的氮,7.1%的硫和9.8%的钠,C:N:S:Na的摩尔比为约10 :1.5:2:4。